GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » FCF Yield %

FibroGen (FibroGen) FCF Yield % : -309.13 (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, FibroGen's Trailing 12-Month Free Cash Flow is $-317.5 Mil, and Market Cap is $102.7 Mil. Therefore, FibroGen's FCF Yield % for today is -309.13%.

The historical rank and industry rank for FibroGen's FCF Yield % or its related term are showing as below:

FGEN' s FCF Yield % Range Over the Past 10 Years
Min: -942.12   Med: -1.87   Max: 5.41
Current: -309.13


During the past 12 years, the highest FCF Yield % of FibroGen was 5.41%. The lowest was -942.12%. And the median was -1.87%.

FGEN's FCF Yield % is ranked worse than
94.32% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs FGEN: -309.13

FibroGen's FCF Margin % for the quarter that ended in Dec. 2023 was -68.44%.


FibroGen FCF Yield % Historical Data

The historical data trend for FibroGen's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen FCF Yield % Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.25 2.29 -8.58 -12.24 -362.74

FibroGen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.01 -22.67 -168.30 -401.72 -84.86

Competitive Comparison of FibroGen's FCF Yield %

For the Biotechnology subindustry, FibroGen's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's FCF Yield % distribution charts can be found below:

* The bar in red indicates where FibroGen's FCF Yield % falls into.



FibroGen FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

FibroGen's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-317.54 / 87.54002826
=-362.74%

FibroGen's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-18.572 * 4 / 87.54002826
=-84.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FibroGen FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


FibroGen FCF Yield % Related Terms

Thank you for viewing the detailed overview of FibroGen's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (FibroGen) Business Description

Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Executives
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158